Sarepta therapeutics' investigational gene therapy srp-9001 for duchenne muscular dystrophy demonstrates significant functional improvements across multiple studies

Cambridge, mass., july 06, 2022 (globe newswire) -- sarepta therapeutics, inc. (nasdaq:srpt), the leader in precision genetic medicine for rare diseases, today shared new functional data across multiple studies from the clinical development program for srp-9001 (delandistrogene moxeparvovec) for the treatment of duchenne muscular dystrophy. srp-9001 is an investigational gene therapy for duchenne being developed in partnership with roche. data are being presented this week at the 17th international congress on neuromuscular diseases (icnmd 2022) in brussels.
SRPT Ratings Summary
SRPT Quant Ranking